Terms: = Bone cancer AND SH2B3, LNK, 10019, ENSG00000111252, Q9UQQ2 AND Treatment
5 results:
1. Co-existence of IL7R high and sh2b3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.
Ge Z; Gu Y; Xiao L; Han Q; Li J; Chen B; Yu J; Kawasawa YI; Payne KJ; Dovat S; Song C
Oncotarget; 2016 Jul; 7(29):46014-46027. PubMed ID: 27322554
[TBL] [Abstract] [Full Text] [Related]
2. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract] [Full Text] [Related]
3. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract] [Full Text] [Related]
4. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract] [Full Text] [Related]
5. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
Tefferi A; Vainchenker W
J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
[TBL] [Abstract] [Full Text] [Related]
